Mallinckrodt looks for higher sales growth in Japan
This article was originally published in Clinica
Mallinckrodt Medical is considering forming a joint venture or making an acquisition in Japan in order to achieve its growth target in that market. Its current sales of around $100 million are growing more slowly than the company would like, reports Japan Medical Review. By 2000, Mallinckrodt aims to see 10% annual sales growth in Japan, says Michael Rocca, the company's vice-president and CFO.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.